ASX biotech stocks rebounded en masse on Monday but there are still concerns Donald Trump's pharma tariffs will cast a shadow over the sector.
Markets
Your complimentary access ends . To keep reading without interruption, subscribe today.
ASX biotech stocks rebounded en masse on Monday but there are still concerns Donald Trump's pharma tariffs will cast a shadow over the sector.
Your email address will be stored in accordance with our privacy policy.